Revvity, Inc. · NYSE:RVTY
Revvity — PerkinElmer — Q2 2022 Earnings Presentation
7 slides from Revvity's earnings presentation, Aug 1, 2022
Slide 1: 2Q22 Earnings Presentation
2Q22 Earnings Presentation August 1, 2022
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: 2Q '22 Financial Results
2Q ‘22 FINANCIAL RESULTS Org. Rev Adj Op Adj EPS Revenue Mix (%) & Organic Growth Highlights Decline -5% Margin 80bps Growth -18% DAS Adjusted Revenue: $1.23 billion; +0% y/y 54% +DD • Organic: -5%; M&A: +10%; FX: -4% DX 46% • COVID: $222 million vs. $365 million in 2Q21 -DD • Non-COVID: +8% organic
Slide 4: Discovery & Analytical Solutions
DISCOVERY & ANALYTICAL SOLUTIONS ✓ +DD organic with Pharma up +DD 2Q22 Performance Food* Life ✓ Discovery +DD driven by strength in Sciences reagents & imaging/detection • +29% reported growth ✓ Informatics up +DD • Organic: +13%; M&A: +20%; FX: -5% • DD growth in Americas & APAC, MSD Ind/Env growth
Slide 5: Diagnostics
DIAGNOSTICS 2Q22 Performance ✓ +LSD organic growth driven by newborn Applied Reproductive Health screening franchise Genomics ImmunoDx • -20% reported decline ✓ Menu expansion, Vanadis growth • Organic: -19%; M&A: +2%; FX: -4% • Non-COVID diagnostics organic ✓ -DD organic driven by COVID declines re
Slide 6: Updated Financial Guidance
UPDATED FINANCIAL GUIDANCE 3Q22 Guidance 2022 Guidance-a) • Adjusted Revenue: $1.02-1.03 billion; -13% to -11% reported • Adjusted Revenue: $4.60-$4.64 billion; -9% to -8% reported • Organic: -17% to -15%; M&A +8%; FX -4% • Organic: -13% to -12%; M&A +7%; FX -3% Assumptions COVID vs. Non-COVID Outlo
Slide 7: Innovating for a healthier world
INNOVATING for a healthier world Steve Willoughby | Vice President, Investor Relations | steve.willoughby@perkinelmer.com | @PerkinElmerIR 7